The novel MDSC-targeting medication NC06 induces MDSC ferroptosis by activating the p53-Hmox1 pathway and decreases MDSC accumulation to stimulate T-cell tumor infiltration and inhibit tumor growth in vivo (70). This evidence concerns the gene TP53 and neoplasm.